Hoth Therapeutics and Acurx Pharmaceuticals invest $1 million in Bitcoin to diversify their assets. As the price of BTC approaches $100,000, this decision illustrates its growing attractiveness to innovative companies.
Biopharma and crypto: Hoth and Acurx invest in Bitcoin
On Wednesday, Hoth Therapeutics and Acurx Pharmaceuticals declared their intention to invest up to $1 million in Bitcoin, according to their respective boards of directors.
These 2 companies in the biopharmaceutical sector are engaged in the research and development of innovative treatments for various pathologies.
Hoth Therapeutics focuses primarily on skin diseases and autoimmune disorders, while Acurx Pharmaceuticals specializes in developing new antibiotics to combat complex bacterial infections.
💡 Discover Dollar Cost Averaging (DCA), an easy method to invest in Bitcoin
In a favorable economic context, marked by a Bitcoin price approaching $100,000 and the election of Donald Trump, An encouraging overall sentiment is emerging for institutional investors and businesses, reinforcing the appeal of Bitcoin as a strategic asset.
With the recent approval of Bitcoin ETFs and increasing activity from institutional investors, this is a solid addition to our treasury strategy. We believe its inflation-resistant characteristics can make it a reliable asset as a functional store of value.
Open an account on N26, the crypto-friendly bank
Bitcoin, a safe haven asset and innovation lever for biopharmaceutical companies
Indeed, Bitcoin, with a limited supply and financial independence allowing it to present itself as a safe haven asset, becomes a unique diversification offer to counter monetary erosion.
As demand for Bitcoin increases, as does its acceptance as a major and primary asset class, we believe Bitcoin will serve as a strong cash reserve asset for unnecessary cash over the next 12 to Next 18 months.
While current international geopolitical tensions impose strong constraints on businesses, the decentralization of Bitcoin makes this asset a healthy solution to the risks of state or institutional interference.
With the recent approval of Bitcoin ETFs and growing support from government agencies and institutional investors, this is a great addition to our treasury strategy. Its limited supply and inflation-resistant features provide a functional store of value. This new cash flow strategy is a financial strategy and has no impact on our overall drug development plans.
Over a decade, Bitcoin has outperformed a number of traditional assets, thus attracting large companies like MicroStrategy and Tesla but also financial institutions such as BlackRock, thus strengthening its legitimacy in these more traditional spheres.
We must also not forget that unlike traditional markets, Bitcoin is traded without a time window, allowing businesses to quickly access liquidity. Ease of implementation reinforced by regulation that is becoming clearer and custody solutions that are becoming simpler.
👉 In the news – Boosted by Bitcoin, MicroStrategy climbs into the top 100 American capitalizations
These press releases are also an integral part of the company differentiation and branding strategy since showing an interest in Bitcoin can be a lever for attracting innovative talent and displaying an avant-garde positioning.
As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe Bitcoin will serve as a strong treasury reserve asset
In an environment “ Bitcoin friendly », BTC represents a real strategic opportunity for companies seeking to secure their cash flow, diversify their assets, and position themselves as leaders in innovation.
€20 offered when you register on Bitvavo
Sources: Hoth Therapeutics; Acurx Pharmaceuticals
The #1 Crypto Newsletter 🍞
Receive a summary of crypto news every day by email 👌
What you need to know about affiliate links. This page may feature investment-related assets, products or services. Some links in this article may be affiliated. This means that if you buy a product or register on a site from this article, our partner pays us a commission. This allows us to continue to offer you original and useful content. There is no impact on you and you can even get a bonus using our links.
Investments in cryptocurrencies are risky. Cryptoast is not responsible for the quality of the products or services presented on this page and cannot be held responsible, directly or indirectly, for any damage or loss caused following the use of a good or service highlighted in this article. Investments related to crypto-assets are risky by nature, readers should do their own research before taking any action and only invest within the limits of their financial capabilities. This article does not constitute investment advice.
AMF recommendations. There is no guaranteed high return, a product with high return potential involves high risk. This risk-taking must be in line with your project, your investment horizon and your capacity to lose part of this savings. Do not invest if you are not prepared to lose all or part of your capital.
To go further, read our Financial Situation, Media Transparency and Legal Notices pages.
A lifelong cyber enthusiast, I have nurtured my curiosity and passion over time… should it have been the other way around? A convinced maximalist, I could have been part of the cypherpunks if I had been born a few years earlier. Convinced that information and knowledge are the ultimate weapons of freedom, I brandish my pen like a sword, defending this noble cause with fervor. Don't take my word for it, check 🐰
